These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24641827)

  • 1. Antithymocyte globulin in the conditioning regimen: why not?
    Bacigalupo A
    Biol Blood Marrow Transplant; 2014 May; 20(5):597-8. PubMed ID: 24641827
    [No Abstract]   [Full Text] [Related]  

  • 2. Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter?
    Hamadani M
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):292-4. PubMed ID: 24394802
    [No Abstract]   [Full Text] [Related]  

  • 3. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
    Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
    Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The comparison of fludarabine or antithymocyte globulin based non-myeloablative conditioning regimen for haematologic diseases with graft-versus-host disease].
    Li QS; Zhuang XY; Mao P
    Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):555-7. PubMed ID: 22338182
    [No Abstract]   [Full Text] [Related]  

  • 6. Graft-versus-host disease--from the bench to the bedside?
    Socié G
    N Engl J Med; 2005 Sep; 353(13):1396-7. PubMed ID: 16192485
    [No Abstract]   [Full Text] [Related]  

  • 7. [A comparative study on early toxicity of conditioning regimen with or without antithymocyte globulin].
    Liu DH; Liu J; Liu KY; Xu LP; Chen H; Chen YH; Han W; Wang Y; Zhang XH; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Aug; 30(8):519-23. PubMed ID: 19954638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
    Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective conditioning for acute graft-versus-host disease.
    Lowsky R; Takahashi T; Liu YP; Dejbakhsh-Jones S; Grumet FC; Shizuru JA; Laport GG; Stockerl-Goldstein KE; Johnston LJ; Hoppe RT; Bloch DA; Blume KG; Negrin RS; Strober S
    N Engl J Med; 2005 Sep; 353(13):1321-31. PubMed ID: 16192477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
    Bitan M; Or R; Shapira MY; Aker M; Resnick IB; Ackerstein A; Samuel S; Elad S; Slavin S
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):712-8. PubMed ID: 16785060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
    Finke J; Schmoor C; Bethge WA; Ottinger HD; Stelljes M; Zander AR; Volin L; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Bertz H; Grishina O; Socié G;
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1716-26. PubMed ID: 22713691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
    Lee KH; Choi SJ; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Yun SC; Joo YD; Lee WS; Kang MJ; Kim H; Park JH; Bae SH; Ryoo HM; Kim MK; Hyun MS
    Am J Hematol; 2011 May; 86(5):399-405. PubMed ID: 21523798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.
    Jaskula E; Lange A; Kyrcz-Krzemien S; Markiewicz M; Dzierzak-Mietla M; Jedrzejczak WW; Czajka P; Mordak-Domagala M; Lange J; Gronkowska A; Nowak J; Warzocha K; Hellmann A; Kowalczyk J; Drabko K; Gozdzik J; Mizia S;
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):409-14. PubMed ID: 24345423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpected outbreak of Epstein-Barr virus post-transplantation lymphoproliferative disorder after hematopoietic stem cell transplantation conditioning with thymoglobulin.
    Yáñez L; Bermúdez A; Insunza A; Romón I; Richard C
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1457-8. PubMed ID: 24972250
    [No Abstract]   [Full Text] [Related]  

  • 17. Company reply to "Unexpected outbreak of Epstein-Barr virus post-transplantation lymphoproliferative disorder after hematopoietic stem cell transplantation conditioning with thymoglobulin".
    Janssen S; Blakolmer K
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):575. PubMed ID: 25542157
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
    Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
    Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymoglobulin and an unexpected outbreak of Epstein-Barr virus.
    Mohty M; Malard F
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):198. PubMed ID: 25459641
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.